with the alert design and implementation. They were not compensated for their contributions. 5. Bansal A, Sullivan SD, Hershman DL, et al. A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study.
Breast Cancer With a Poor Prognosis Diagnosed After Screening Mammography With Negative Results
Approximately 15% of breast cancers are diagnosed after the patient undergoes screening mammography with negative results and before the next recommended screening examination. 1 These interval cancers (cases of cancer diagnosed during the interval between examinations) include both cancers that were present during screening mammography but were missed on examination and rapidly growing cancers that present symptomatically and tend to have a poorer prognosis than cancers detected during screening. [1] [2] [3] Identifying women who are at high risk of breast Among all patients, use of G-CSF did not change after the implementation of an alert in the electronic health record. ICU indicates intensive care unit.
cancer with a poor prognosis despite regular screening mammography could enable targeted supplemental screening for women for whom screening mammography may not be sufficient. This study describes the incidence of and risk factors associated with breast cancer with a poor prognosis after screening mammography with negative findings. a P value from χ 2 test comparing distribution of breast cancer cases with good vs poor prognosis by screening mammography result. b Breast cancer with poor prognosis was defined as cancer with distant metastases; regional lymph nodes positive for cancer; estrogen receptor-positive and/or progesterone receptor-positive and HER2-negative cancer 2 cm or more in diameter; estrogen receptor-negative, progesterone receptor-negative, HER2-negative cancer (triple-negative breast cancer) 1 cm or more in diameter; or HER2-positive cancer 1 cm or more in diameter. were classified as having positive results. Cancer diagnoses within 1 year after screening mammography were obtained from state cancer registries. Breast cancer cases with a poor prognosis were defined as cases of cancer meeting any of the following criteria: distant metastases; cancer-positive regional lymph nodes; estrogen receptor-positive and/or progesterone receptor-positive and HER2-negative invasive cancer 2 cm or more in diameter; estrogen receptornegative, progesterone receptor-negative, HER2-negative (triple-negative) invasive cancer 1 cm or more in diameter; or HER2-positive invasive cancer 1 cm or more in diameter. This definition is the primary outcome for the ongoing Tomosynthesis Mammographic Imaging Screening Trial. 5 Multivariable logistic regression was used to assess the association of age, breast density, and family history with cancer diagnosis. SAS software, version 9.4 (SAS Institute Inc) was used for all analyses. P ≤ .05 was considered statistically significant, and all P values were 2-sided.
Results | Table 1 provides the incidence of breast cancer among 306 028 women 40 years or older who had no earlier diagnosis of breast cancer and underwent mammography screening between 2011 and 2014. Cases of cancer diagnosed after screening mammography with negative results were more likely to be associated with a poor prognosis (43.8%) than those diagnosed after mammography with positive results (26.9%). Among all women with negative mammography results ( Discussion | Our results indicate that the positive predictive value of mammography results depends on patient age and family history but not on breast density. In contrast, the negative predictive value depends on breast density but not on patient age or family history. Although the rate of breast cancer after negative mammography results is small, the likelihood that such cases will be associated with a poor prognosis highlights the need to improve early detection for these women. Although breast density is predictive of interval cancer overall, it is less predictive of whether that interval cancer will have a poor prognosis. Younger age is predictive of interval breast cancer with a poor prognosis. This may reflect the dual origins of interval cancers. Cancers that are present but not detected by screening mammography may be more likely to be associated with a good prognosis and occur among older women, whereas cancers that develop between screening examinations may be more likely to be rapidly growing cancers associated with a poor prognosis and occur among younger women. Only a few patient characteristics were available, limiting the number of risk factors that were assessed. Breast density has received much attention as the primary factor identifying a need for supplemental screening, but considering both breast density and age may be more effective in identifying women who are at risk for breast cancer with a poor prognosis.
Implications of Screening for Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer
Brain metastases affect many patients with cancer. 1 Given the limited intracranial penetration of most systemic therapies, the size and number of brain metastases at diagnosis determines management, with more invasive or toxic therapies such as neurosurgical resection and whole brain radiation therapy Table 1 ) and as a time-to-event based outcome (hazard ratio, 1.54; 95% CI, 1.10-2.17; P = .01; Table 2 ).
Discussion | Patients with breast cancer presented with more advanced intracranial disease than did patients with NSCLC and more frequently required WBRT as initial management. However, after initial brain-directed therapy, no differences in recurrence or salvage therapy-based outcomes between the 2 cohorts were noted. This finding suggests that intracranial disease in patients with breast cancer was not more aggressive or resistant to treatment but rather was diagnosed at a later stage. Brain-directed MRI screening for patients who harbor malignant neoplasms with potential for intracranial involvement is important given the impact of neurological compromise on quality of life. In addition, early identification of intracranial disease facilitates less invasive or less toxic approaches, such as stereotactic radiosurgery or careful use of promising systemic agents rather than WBRT or neurosurgical resection.
The limitations of our study include its retrospective nature, inherent selection bias, and potential clinical confounders. In addition, 84 patients with breast cancer (24.0%) were screened for brain metastases (eg, patient/provider preference, clinical trial)-representing a higher percentage than in previous studies, which screened less frequently 5 -whereas Table 1 . Women had significantly higher rates of all-grade nausea, vomiting, constipation, cramping, stomatitis, cholinergic syndrome, lethargy, alopecia, leukopenia, neutropenia and anemia. Overall toxic effects and differences between women and men were numerically increased with FOLFIRI ( Table 2 ). Significantly higher rates of all-grade constipation, nausea, vomiting, alopecia, leukopenia, neutropenia, and anemia in women were observed regardless of treatment (fluorouracil/leucovorin or FOLFIRI). The significantly higher risk for leukopenia, anemia, alopecia, and vomiting for women was not affected by age. Grade 3 or 4 AEs significantly more frequent in women in pooled treatment arms (Table 1) were alopecia, stomatitis, diarrhea, nausea, leukopenia, neutropenia, and anemia. Under treatment with FOLFIRI, but not fluorouracil and leucovorin, significant differences between men and women were seen for grade 3 or 4 alopecia, stomatitis, diarrhea, and lethargy ( Table 2 ). The higher incidence of grade 3 or 4 neutropenia in women treated with FOLFIRI was independent of age and BMI. Dose reductions were more frequent in women vs men (341 [25.9%] vs 279 [16.8%]; P < .001), especially under treatment with FOLFIRI.
Discussion | This analysis is the largest to date that systematically addresses the association of sex with all types of toxic effects of standard fluorouracil with or without irinotecan chemotherapy in CRC. It demonstrates a statistically significant and clinically relevant greater risk of nonhematological and objectively measurable hematological AEs in women. Female sex has previously been identified as a risk factor for irinotecan-induced neutropenia. 4 As UGT1A1 polymorphisms do not vary with sex, 5 they cannot explain the observed differences in toxic effects caused by irinotecan. These differences must be either pharmacokinetic, as demonstrated for fluorouracil, or pharmacodynamic. In an age of personalized medicine, and also considering growing knowledge about sex-related differences in molecular profiles and disease biology, 6 the potential effect of sex on efficacy and toxic effects of systemic treatments in oncology deserves more awareness and further investigation. Drug targets, but also the optimal dose necessary to hit a target with an acceptable level of toxic effects, may be different between men and women. 
Surrogate Markers and the Association of Low-Dose CT Lung Cancer Screening With Mortality
Based on surrogate markers of benefit, single-arm studies projected that lung cancer screening with computed tomography (CT) would reduce lung cancer mortality by 80%. 1 Yet subsequent randomized clinical trials produced findings ranging from no reduction to a 20% reduction. 2 We formally evaluated the seemingly misleading surrogates.
Methods | In each of the 33 separate sites of the randomized National Lung Screening Trial (NLST) 3 we assessed the relation between the magnitude of the actual benefit observed and 3 separate surrogates of benefit: 1. The proportion of stage 1 lung cancers diagnosed in the CT arm out of all lung cancer diagnoses, with a logarithmic transformation applied to improve adherence to mathematical assumptions. 2. Lung cancer-specific survival at 4 years among participants in the CT arm found to have stage 1 lung cancer (median follow-up was 53 months), with censoring was either for death from another cause or end of follow-up. 3. The ratio of the proportion of stage 1 lung cancers diagnosed between the study arms, with a logarithmic transformation applied. 4 Using a weighted Pearson correlation coefficient (weights were the total number of lung cancer diagnoses at the study unless otherwise noted), we evaluated the relation between each surrogate and the difference in rates of death from lung cancer in the CT arm vs the chest x-ray (CXR) arm. Two sided P values <.05 were considered statistically significant. Statistical analyses were performed using R statistical software (version 3.2.2, R Foundation) including the weights and car packages. The NLST is a public use file exempt from institutional review board approval or written informed consent.
Results | We analyzed data from 26 722 CT patients and 26 730 CXR patients, for a total of 53 452 patients. The mean (SD) age was 61 (5) years, with 31 530 (59%) men. The site-level magnitude of lung cancer mortality reduction was not associated with either the proportion of stage 1 lung cancers diagnosed in the CT arm (Pearson correlation, -0.08; 95% CI, -0.41 to 0.27; P = .65) or 4-year lung cancer-specific survival rate of participants in the CT arm diagnosed with stage 1 lung cancer (Pearson correlation, -0.28; 95% CI, -0.58 to 0.09; P = .13) (Figure) . The difference in the proportion diagnosed with stage 1 lung cancer between study arms (means, CT 54% and CXR 34%; P < .001) was neither correlated with the difference in lung cancer mortality (Pearson correlation, -0.28; 95% CI, -0.57 to 0.07; P = .12) nor did it attenuate the main effect of the intervention in a regression analysis (P < .001) (Table) .
Discussion | Good surrogate markers of important endpoints can make studies more efficient; poor ones can be misleading. Early single-arm studies of CT screening that used surrogate markers estimated that CT screening would reduce lung cancer death by 80% or more; later randomized clinical trials estimated a benefit ranging from 0% to 20%. The recently published randomized Danish Lung Cancer Screening Trial (DLCST) 5 illustrates the problem clearly. Although there was clear evidence that CT screening was associated with a far higher rate of stage 1 lung cancer diagnoses than the control group (50 vs 8, P < .001), lung cancer deaths in the 2 arms were essentially equal (39 screening vs 38 usual care).
5
Some researchers have considered improvements in surrogate markers of screening benefits to be synonymous with evidence that CT screening is improving patient outcomes. 6 Yet our analysis suggests that drawing such a conclusion is inappropriate. We conclude that these surrogate markers must not be used to evaluate the benefits of CT screening. We base this on not only our analyses, but the observation that these surrogate markers have been poor at predicting CT screening benefits both between and within studies, and the basic epidemiologic biases associated with screening, such as length biased sampling, are known to inflate the surrogates without improving outcome. A quest for more reliable predictive markers of CT screening impact on patient outcomes is warranted. Lack of statistical relation between study site-level effect of computed tomography (CT) screening on lung cancer mortality compared with control arm compared with 2 surrogate markers of that benefit-proportion of stage 1 lung cancers in the CT arm of the study (solid regression line, P = .65); 4-year lung cancer specific survival among those with stage 1 lung cancer in the CT arm (dashed regression line, P = .13). In each case the slope of the regression lines is more consistent with a negative than a positive correlation between these surrogates and the impact of CT screening on lung cancer mortality. The circles represent the site-level data points for the proportions of stage 1 lung cancers, the triangles represent the site-level data points for the 4-year survival rates in the CT arm. 
US Public Perceptions About Cancer Care Provided by Smaller Hospitals Associated With Large Hospitals Recognized for Specializing in Cancer Care
Over the past 5 years, smaller hospitals have developed formal relationships with larger hospitals at a historic rate, with more than 100 new mergers, acquisitions, and affiliations being filed each year in the United States. 1, 2 Applying the brand of a larger hospital to smaller, affiliated hospitals has become commonplace. 3 This brand sharing has the potential to influence patient decisions about where to pursue care, particularly for complex conditions such as cancer. 4 However, the extent to which patients perceive the care at the smaller hospitals to be affected by affiliation is unclear. In an effort to understand patient expectations associated with brand sharing for complex cancer care at smaller hospitals, we surveyed a nationally representative sample in the United States.
Methods | An internet KnowledgePanel survey (GfK Group) was distributed across a nationally representative adult sample in November 2017. 5 Respondents were asked to consider a smaller hospital developing a relationship (affiliation) with a larger hospital recognized for specializing in cancer care, and questioned regarding the impact of the affiliation on the smaller hospital (questionnaire available on request). To account for variable response rates across sociodemographic strata, results were weighted (using age, sex, race, region, metropolitan area, income, education, and home ownership) to mirror the US population and are reported with 95% confidence intervals (CIs). The study was approved by the Yale University Human Investigations Committee, which provided a waiver of written informed consent. Respondents were not compensated directly, but were periodically entered into raffles run by GfK group to encourage participation. Overall, 943 (94%) respondents felt that cancer care at a smaller hospital would improve after affiliating with a larger hospital specializing in cancer. A total of 131 (14%) respondents believed improvement would happen right away, 392 (39%) within 6 months, and 738 (73%) within a year. After affiliation, respondents expected physicians at the larger hospital to be involved considerably in the care of patients at the smaller hospital ( Table 1) . Most respondents (594 [60%]) believed physicians from the larger hospital were "often" or "always" involved in at least 1 of 5 potential areas of care integration. Specifically, 922 (92%) respondents expected surgeons from the larger hospital to operate at the smaller hospital, including 308 (32%) who felt this would take place "often" or "always" (Table 1) .
Results
Regarding the impact of affiliation on patient choice, 785 (77%) respondents indicated they would choose to have complex cancer surgery at a smaller hospital that was affiliated with a larger hospital over a smaller hospital without an affiliation. Abbreviation: NA, not applicable. a Survey questions were developed using focus groups and pilot surveys prior to the final study distribution. To achieve a nationally representative sample, the survey was repeatedly distributed using a probability-based sampling method to mirror the US population until a minimum of 1000 surveys were completed. A total of 1738 were distributed for a response rate of 58.1%. Sixteen surveys were excluded because they were incomplete. b To account for variable response rates across sociodemographic strata, survey responses were weighted (age, sex, race/Hispanic ethnicity, education, region, household income, home ownership status, and residence in a metropolitan area) to maintain the sociodemographic profile of the US population. For each question, the proportion of respondents choosing not to answer was less than 2% (nonresponses not shown, therefore row total may not equal 100%). c In all, 594 (59.9%) respondents chose "often" or "always" for at least 1 of the 5 previously asked questions listed in table regarding care integration (95% CI, 56.8-63.1). Because respondents tended to vary their responses across the questions in this table (did not choose the same frequency for each care element), the prevalence of respondents that chose "often" or "always" for at least 1 of the questions was higher than the prevalence in any individual question.
Letters
When asked about distinguishing aspects of the care provided by the smaller, affiliated hospital, 484 (47%) felt the care was more guideline compliant, 474 (47%) believed it was safer, and 368 (37%) felt it was more likely to be curative compared with a smaller hospital without an affiliation ( Table 2) .
Discussion | The survey results illustrate both the perceived favorable impact (which is not uniform) and potential influence of hospital affiliations in the United States. There is a clear public expectation that physicians working at larger hospitals participate in the care of patients at smaller, affiliated hospitals (as opposed to simply providing smaller hospital physicians appointments at the larger hospital), yet there are some obvious geographic and temporal barriers that could limit this in practice. Understanding the perceived impact of affiliation on smaller hospitals is particularly relevant, because most US patients receive complex cancer care at smaller hospitals. 6 It is the responsibility of the involved hospitals to understand patient expectations when the brand of a recognized cancer hospital is presented at a smaller hospital, and either comply with those expectations or clarify their advertising. a Survey questions were developed using focus groups and pilot surveys prior to the final study distribution. To achieve a nationally representative sample, the survey was repeatedly distributed using a probability-based sampling method to mirror the US population until a minimum of 1000 surveys were completed. A total of 1738 were distributed for a response rate of 58.1%. Sixteen surveys were excluded because they were incomplete. b To account for variable response rates across sociodemographic strata, survey responses were weighted (age, sex, race/Hispanic ethnicity, education, region, household income, home ownership status, and residence in a metropolitan area) to maintain the sociodemographic profile of the US population. For each question, the proportion of respondents choosing not to answer was less than 2% (nonresponses not shown, therefore row total may not equal 100% We suspect that classification of "kidney cancer" in the study by Samadder et al 1 likely represents UTUC involving the renal pelvis, which in this study may or may not involve ureteral cancer. This misclassification unfortunately will add to the current and future confusion of researchers, clinicians, and patients who try to understand this enigmatic disease. Upper tract urothelial carcinoma is increasingly recognized as a unique disease that appears to have genomic differences from its lower urinary tract counterpart in the bladder, 5,6 despite phenotypic similarity. We would ask the authors to investigate this concern and consider a clarification for the benefit of accurate reporting and to facilitate future research endeavors that will build on this otherwise outstanding study, to reliably reflect these findings.
In Reply
We thank Drs Matin and Coleman for their informative letter regarding our article. 1 On review of the literature cited by the authors, we agree that there is confusion regarding the nomenclature describing genitourinary malignant neoplasms, especially as it applies to grouping of upper tract urothelial malignant neoplasms separately from renal cell carcinomas. In reviewing our study results, we can confirm that carcinomas of the renal pelvis and ureter were included in the more global label of "kidney cancer." The total numbers of lesions in our study (using the Utah Cancer Registry) for each of these cancer sites were 5138 kidney carcinoma, 476 renal pelvis carcinoma, and 294 ureter carcinoma.
The number of nonkidney upper genitourinary tract cancers (ie, ureter and renal pelvis) was small compared with the number of kidney cancers in the proband members identified as Amsterdam I or II cases. We do acknowledge, however, that on a preliminary reanalysis of the data that in Amsterdam I families, the increased risk of genitourinary cancers in first-degree relatives is being driven by renal pelvis and ureter cancers. Going forward, we will make this important distinction between kidney carcinoma and upper genitourinary tract cancers.
When You Hear Hoofbeats, Look for Horses, Not Zebras
To the Editor We read the article by Hung et al 1 with great interest. If anaplastic lymphoma kinase (ALK) rearrangements in peritoneal mesothelioma could be incorporated into the treatment, it would be a godsend for patients. However, we would like to address 1 concern about the diagnosis. ALK rearrangements are extremely rare events in malignant mesothelioma as they mentioned. 2 When we make a diagnosis, it is important to look for the simplest hypothesis. How about the possibility of primary peritoneal carcinomas with ALK rearrangements? Primary peritoneal carcinomas are as rare as peritoneal mesothelioma, 3 and similar to ovarian carcinomas, which are known to harbor ALK rearrangements. 4 The patient characteristics of younger age, female sex, expressed mesothelial markers (keratin AE1/AE3, calretinin, and WT1), and retained BAP1 expression are consistent with primary peritoneal carcinomas. 5 We want to know more details about the 3 ALK-positive cases in terms of the differentiation from primary peritoneal carcinomas.
Yuki Kataoka, MD, MPH Azusa Sakurai, MD Emiko Saito, MD
In Reply After the publication of our study identifying anaplastic lymphoma kinase (ALK) rearrangements in peritoneal mesothelioma, 1 we read the Letter by Kataoka et al with skepticism. Because both peritoneal mesothelioma and primary peritoneal carcinoma are rare intra-abdominal tumors, Kataoka et al wonder whether our 3 cases of ALK-rearranged peritoneal mesothelioma may represent misdiagnoses and are instead primary peritoneal carcinomas with ALK rearrangement. We address their concern as follows. First, Kataoka et al inquired about the differentiation status of ALK-rearranged peritoneal mesotheliomas, wondering whether they may represent epithelial tumors such as primary peritoneal carcinomas rather than malignant peritoneal mesotheliomas. As detailed in our study (including the online-only Supplement), 1 all cases demonstrate mesothelial rather than epithelial differentiation, as confirmed by clinicopathologic features, immunohistochemistry, and electron microscopy. All ALK-rearranged peritoneal mesotheliomas show an immunohistochemical phenotype typical of mesothelioma. All tumors in our study are positive for mesotheliomaspecific markers (calretinin, WT1, and podoplanin [D2-40]) and are negative for carcinoma-specific markers (claudin-4, BerEP4, and polyclonal carcinoembryonic antigen). 2 Kataoka et al have erroneously implied that retained BAP1 protein expression rules out the diagnosis of malignant mesothelioma and suggests carcinoma instead. However, because loss of BAP1 protein expression is found in only 40% to 60% of peritoneal mesothelioma, 3 retained BAP1 protein expression does not rule out the diagnosis of mesothelioma at all. Furthermore, we have demonstrated by electron microscopy the presence of long thin apical microvilli and prominent desmosomes, features that are characteristic of malignant mesothelioma and incompatible with peritoneal carcinoma. 4 Second, the Letter by Kataoka et al confuses the concept of aberrant ALK protein expression with ALK gene rearrangement. They have mistakenly implied that ALK rearrangement is present in primary peritoneal carcinoma, citing the study by Ren et al. 5 The study by Ren et al showed aberrant
ALK expression in a subset of primary peritoneal carcinomas, which is due to copy number gain but not bona fide gene rearrangement of ALK. In fact, as demonstrated by Ren et al 5 and
others, 6 all primary peritoneal carcinomas examined lack bona fide ALK gene rearrangement. In contrast, we have confirmed in our cases of peritoneal mesothelioma the presence of bona fide ALK gene rearrangements using both fluorescence in situ hybridization testing and targeted DNA/RNA sequencing.
1
Given the rarity of peritoneal mesothelioma, its diagnosis can be challenging. Nonetheless, the diagnosis of peritoneal mesothelioma and its distinction from peritoneal carcinoma can be straightforward with judicious application of select diagnostic tools, provided that one understands their utilities and limitations. There were 111 carriers of a BRCA1 or BRCA2 mutation identified, 29 carriers of a CHEK2 mutation, 1 carrier of an NBN mutation, and 1 carrier of a BRIP1 mutation. The authors use these data to support their position that use of a 23-gene panel is preferable to testing for BRCA1 and BRCA2 alone. We look at the same data and conclude that testing should be limited to BRCA1 and BRCA2.
The claim in the abstract that all the patients' mutations were "responsible for their disease" is not warranted. is probably not pathogenic, and to counsel a family member otherwise is problematic. Second, 1 BRIP1 truncating mutation was reported; however, a recent collaborative study of more than 100 000 persons found no evidence for an association between BRIP1 truncating variants and breast cancer risk. 2 Third, 24 women carried a CHEK2 founder allele (S428F). The odds ratio for this allele (2.13) is based on a single report. 3 Based on a 2-fold risk, it is not obvious that any specific case of breast cancer is the consequence of the genetic mutation (half would not be). Women at 2-fold risk are not candidates for mastectomy and are unlikely to take tamoxifen, and there are no empirical data that disclosing moderate risk is effective policy. Counseling for CHEK2 mutations is difficult. 4 We have a recent example in which the proband with breast cancer had a mutation and this variant was present in the daughter. After the daughter was counseled to be at high risk, her affected sister was tested and found to be negative for CHEK2 mutation.
In cancer families, the number of BRCA mutations will greatly outnumber the CHEK2 mutations. In the general population, CHEK2 mutations greatly outnumber BRCA mutations. 5 If population-based testing is enacted, the majority of our counseling time will be devoted to women with low-penetrant CHEK2 alleles.
In summary, we argue against replacing a 2-gene test for Jewish women with a 23-gene panel and we believe that to do so will lead to unnecessary worry and unwarranted interventions and will not lessen the cancer burden. We agree that testing Jewish women for BRCA1 and BRCA2 should include scanning the entire sequence of BRCA1 and BRCA2 for mutations and should no longer be restricted to founder mutations. We have already adopted this practice in Canada.
Steven Narod, MD Victoria Sopik, MSc Cezary Cybulski, MD In Reply Narod et al raise several concerns about our recent suggestion that women of Ashkenazi Jewish (AJ) ancestry consider comprehensive sequencing for inherited predisposition to breast and ovarian cancer. Our data 1 led us to suggest that, given recent advances in sequencing technology and reductions in price, AJ women consider the same complete sequencing for all known breast cancer genes as women of other ancestries. Dr Narod has made enormous contributions to translation of the science of breast cancer genes to the clinic. We appreciate the opportunity to discuss these issues with him. We continue to believe in the importance to AJ women of multigene sequencing, for several reasons.
Most inherited predisposition to breast cancer among AJ women is due to 1 of the 3 AJ founder mutations in BRCA1 or BRCA2. Our recent project demonstrated that among AJ women with inherited predisposition to breast cancer due to a mutation other than 1 of these 3 founder alleles, most of the critical mutations are individually rare-even private-and may lie in any of the known breast cancer genes.
1 Only comprehensive sequencing can detect all these mutations. A recent case from our laboratory illustrates this point. The participant in question is 34 years old, of AJ ancestry, and cancer free, with a severe history of breast and ovarian cancer in her mother's family. An affected cousin carried BRCA1_185delAG. The participant's mother had undergone risk-reducing surgery 25 years ago and is cancer free. The participant is negative for all 3 AJ founder mutations. Nonetheless, knowing the results of our project, she undertook multigene panel testing. She carries a nonsense mutation in RAD51D, which significantly increases her risk of ovarian cancer 2 and possibly also her risk of triple-negative breast cancer. 3 Absent comprehensive sequencing, this participant's RAD51D nonsense mutation would not have been detected. With comprehensive sequencing, the greatest challenge to the field is not identifying mutations but interpreting them. Risks vary by gene and by cancer. For example, loss-offunction mutations in BRIP1 significantly increase risk of ovarian cancer, 2 whereas effects on breast cancer risk are still unclear. 4 Mutations in NBN are proving to have at most marginal effect on either ovarian or breast cancer risk. We agree that only unambiguously loss-of-function mutations, in genes with clear effect on risk, should be reported to patients as pathogenic. Understanding these risks will improve as many more cases and appropriate controls are evaluated. CHEK2 merits special comment. CHEK2 p.S428F was the most common mutation among AJ breast cancer patients negative for the BRCA1 and BRCA2 founder alleles.
1 CHEK2 p.S428F
increases breast cancer risk 2-fold. 5 CHEK2_1100delC, a panEuropean allele, increases breast cancer risk 2-to 3-fold. The combined frequency of these alleles in the cancer-free AJ population is approximately 1.7%. Ashkenazi Jewish women who carry 1 of these alleles could benefit from more frequent mammography or magnetic resonance imaging. Finally, intermarriage has introduced mutations from multiple breast cancer genes into the AJ population. For women of AJ ancestry, as for women generally, the most effective way to identify these mutations is comprehensive sequencing. great interest, and congratulate the authors on their excellent work. As the authors correctly state, this study is the first offlabel study of which we are aware of propranolol for melanoma treatment. 1 However, I would like to call attention to several points that need further clarification. Research has reported that propranolol inhibits melanoma growth in a U-shaped biphasic manner. 2 Low propranolol doses lead to a significant melanoma growth inhibition, whereas higher doses are progressively less effective. 2 There is also evidence that propranolol is metabolized via 4-hydroxylation by CYP2D6, a highly polymorphic enzyme, and that CYP2D6 genetic polymorphism has a significant effect on its pharmacokinetics. 3 Furthermore, among the β-blockers, propranolol demonstrates a high level of inverse agonism 4 and it can also act as a partial agonist, having important consequences on cancer cell proliferation, invasion, and migration. 5 The findings of De Giorgi and colleagues add substantial information to previously published data, but evaluating these additional points would be useful for better improving the propranolol treatment of melanoma.
Salvatore Patanè, MD
In Reply We are grateful to Dr Patanè for his comments and suggestions about issues that give us the opportunity to consider additional properties of propranolol that may be of importance to interpret our results. Propranolol is an archetypical drug in terms of both pharmacokinetic and pharmacodynamic complexity. Together with polymorphisms of metabolic enzymes, additional factors, such as age, smoking, xenobiotics, and food, modulate plasma concentrations, contributing to variable pharmacokinetic profiles in different individuals. 1 The recently reported U-shaped dose-response curve for the inhibition of melanoma growth supports the dose dependency of propranolol effects. On the other hand, it is well known that similar propranolol concentrations exert multifaceted pharmacological effects. In addition to unselective agonism of β 1 -and β 2 -adrenergic receptors, propranolol acts as an inverse agonist or partial agonist, with an unexpected G protein-and β-arrestinindependent mechanism, 2 and it is also likely to target the β 3 -adrenergic receptor, which increasing evidence supports as a player in melanoma growth. 3 Finally, evidence is accumulating about immunological mechanisms that may mediate synergistic effects of propranolol and immunotherapy. 4, 5 The complexity of the pharmacological profile of propranolol does not decrease its therapeutic potential, but rather increases its value as a tool to identify novel mechanisms involved in melanoma proliferation. Future studies should address critical questions, such as the relationship between plasma concentrations or pharmacogenetic profile and outcome, to both optimize therapeutic dosages and identify candidate populations to an increased responsiveness. Thirty years after the Nobel Lecture by Sir James W. Black, OM, FRS, FRSE, FRCP, 6 this low-cost small molecule continues to surprisingly honor the initial promises for health amelioration. 
Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemia
To the Editor We applaud Sorror and colleagues 1 for systematically investigating the association of comorbidities with the risks of mortality in patients with acute myeloid leukemia (AML). As the authors pointed out, more than half of new AML cases are diagnosed in adults aged 60 years and older. 2 The optimal treatment for this vulnerable group is unclear, and practice patterns vary in this population. Comorbid conditions are prevalent in older adults with AML, and prior studies have reported that between 36% and 45% of older patients have significant comorbidities (Hematopoietic Cell TransplantationComorbidity Index score of >1). 3, 4 Although the proposed AML composite model is not specific to older adults, it has the potential to help guide oncologists in selecting treatment for this population. Given the evidence supporting the feasibility and utility of comorbidity assessment in AML, a next logical step is to integrate comorbidity screening routinely into multisite AML trials. The burden is low and potential yield is high. In addition to comorbidity, we would like to highlight the importance of additional measured patient characteristics that may further refine risk estimation for older adults with AML. Among older adults in particular, comorbidity alone does not adequately capture the phenotypic heterogeneity that underlies vulnerability or frailty. Studies investigating geriatric assessment among older adults receiving treatment for AML have highlighted physical and cognitive function as key parameters that may influence survival. Among older adults receiving intensive induction, impaired objectively measured physical function (hazard ratio [HR], 2.3; 95% CI, 1.03-5.1) and cognition (HR, 3.0; 95% CI, 1.3-6.9) were stronger predictors of overall survival compared with age (HR, 1.3; 95% CI, 0.8-2.0) and comorbidity (HR, 1.2; 95% CI, 0.7-2.2) in older adults with AML. 3 Deschler and colleagues 5 similarly demonstrated that impaired function (HR, 2.1; 95% CI, 1.1-3.9) was a stronger predictor of overall survival compared with comorbidity (HR, 2.0; 95% CI, 1.1-3.4) in older patients with AML or myelodysplastic syndrome receiving nonintensive therapy. Taken together, we need to take 1 step further and incorporate measures of physical function and cognition, in combination with comorbidity, when assessing the risks of mortality, especially in patients with AML.
Kah Poh Loh, MBBCh, BAO Heidi Klepin, MD
We would like to point out that we developed and validated the AML-composite model (AML-CM) in all adults with AML because we believe that physiologic rather than calendar age should be used for purposes of treatment decision making. It is a commonplace observation that adults younger than 60 years with significant comorbidity burden are "physiologically older" than older individuals who have fewer comorbidities. For example, in our study, 1 there were 16 patients with a median age of 52.5 (range, 22-59) years whose AML-CM scores of 12 to 15 mainly reflected a relatively high augmented Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) score (median score, 11; range, 8-13). Six of these 16 (38%) died. In contrast, there were 15 patients who, despite a median age of 71 (range, 66-82) years, all had augmented HCT-CI scores of 0 and corresponding AML-CM median scores of 3 (range, 2-4) that solely reflected their older age and "adverse" cytogenetic abnormalities. Three of these 15 patients died (20%). We cannot overemphasize the importance of not merely looking at age-for example, younger vs older than 60 years-when deciding on therapy for AML or considering comprehensive health profile assessment. Nonetheless, clinical trials are commonly divided into those for people younger vs older than 60 years, a practice that we hope to change by the use of the AML-CM. We agree on the importance of integrating comorbidity screening routinely into multisite AML trials. A step in this direction was the design of a web-based calculator (www .AMLCompositeModel.org). We have also completed a prospective study looking at patient questionnaire-based and claims-based methods for collecting comorbidities. One or both of these methods, if proven as efficient as medical record-based methods, could be used in the future to calculate comorbidity scores for patients with AML in collaborative trials.
Drs Loh and Klepin correctly point out that health burdens of older patients extend beyond comorbidities. Physical, cognitive, and functional health have been shown to predict AML outcomes. Other variables such as socioeconomic status and social health might also play a role. A large multicenter study is needed to investigate which of these parameters should be added to the AML-CM for a more comprehensive health assessment of older patients before treatment of AML. As a preliminary step, we have completed a study collecting geriatric and quality-of-life data on 705 patients with newly diagnosed AML (NCT01929408) with the intent of expanding the AML-CM to include predictive geriatric and quality-of-life variables. Validation of our findings at other institutions will be important but requires an agreement on a battery of tools to be used in AML. Such agreement warrants a national collaboration across all AML collaborative groups.
Once these studies are completed, we should be able to arrive at some consensus regarding the best way to predict outcome in older, but also in some younger patients. This method could then be used to compare outcomes in various studies with those expected based on predictions.
new-initiator design, and accounted for unexposed person-time. 4 Outright exclusion of prevalent users from survivor studies precludes an understanding of how prediagnosis statin use affects tumor phenotypes and other prognostic factors. These are critical questions, given that 1 in 4 US adults 40 years or older uses a statin. 5 A sizable proportion of patients with cancer are unlikely to be statin naive at diagnosis. While the emulated trial provides a warning about the pernicious influences of selection and immortal time bias on observational research, it should not diminish enthusiasm for conducting trials of statins in cancer survivors, nor should it discourage other well-designed nonrandomized research.
Thomas P. Ahern, PhD, MPH Signe Borgquist, MD, PhD Deirdre P. Cronin-Fenton, PhD ing our pooled analysis of previous studies to 8 studies with less than 5 years of follow-up (median, 3.1 years), the randomeffects hazard ratio of all-cause mortality for any statin vs no statin use was 0.69 (95% CI, 0.52-0.86; P < .001 for heterogeneity). Given the comparably longer follow-up of their study, we invite Chan et al to support their argument empirically by reporting their own effect estimates in analyses that restrict the duration of follow-up at 3 to 5 years.
Both Ahern et al and Chan et al find our null results surprising because, in their view, the effect of statin therapy on all-cause mortality is well established. Our null estimates are, however, consistent with the null association between statin use and all-cause mortality in individuals aged 65 years or older (the same age group as in our study) from a large randomized primary prevention trial 2 that reported a hazard ratio of 1.18 (95% CI, 0.97-1.42) for pravastatin vs usual care over 6 years of follow-up. Ahern et al express concern about outright exclusion of prevalent users because a sizable proportion of patients with cancer are not statin naive at diagnosis. Again, we agree. However, the question of interest for these patients is not whether to initiate statin therapy (which they are already taking), but rather whether to stop statin therapy, switch drug, or change dose. Therefore, the observational analysis of prevalent users needs to emulate a target trial of, say, statin discontinuation rather than, as we did, of statin initiation. Unfortunately, unbiased emulation of a trial of statin discontinuation in recently diagnosed cancer patients may not be possible using the available data sources: the strong association between discontinuation and poor cancer prognosis is likely to induce intractable confounding.
In conclusion, our study 1 suggests that biases in prior observational studies may have resulted in an exaggerated estimate of the benefits of statins as a cancer treatment. We encourage future analyses and reanalyses of observational data that eliminate those sources of bias and that have a long followup. Randomized trials of statins in patients with cancer, if conducted, need to be designed with sufficiently large sample sizes to obtain precise estimates of potentially small effects.
Louise Emilsson, MD, PhD Xabier García-Albéniz, MD, ScM, PhD Miguel A. Hernan, MD, MPH, ScM, DrPH patients with nonsquamous non-small cell lung cancer in our cohort at the 6-week landmark analysis of progression-free survival (PFS), with 43 of these patients having a PD-L1 TPS of less than 50% and 11 a PD-L1 TPS of 50% or greater. These numbers are too small to allow detection of a statistically significant difference in PFS in either subgroup between individuals with irAEs and those without irAEs. However, there was a nonsignificant finding of a longer PFS in patients with irAEs than in those without such events for the subgroups with either a low (hazard ratio, 0.58; 95% CI, 0.29-1.16; log-rank P = .12) or high (hazard ratio, 0.19; 95% CI, 0.008-2.05; log-rank P = .16) PD-L1 TPS. Although further studies will be needed to confirm these preliminary findings, they suggest that the occurrence of irAEs may be predictive of nivolumab efficacy at least in part in a manner independent of the PD-L1 expression level on tumor cells.
